No registrations found.
ID
Source
Brief title
Health condition
Eosinophilic asthma, action of mepolizumab on lung inflammation.
Sponsors and support
Intervention
Outcome measures
Primary outcome
change in kinetics of eosinophils in the sputum
Secondary outcome
change in kinetics of eosinophils in the sputum
change in systemic cytokines
change in sputum markers for presence of eosinohils
Study objective
Eosinophils play an important role in the inflammatory processes in the lung of asthmatic patients. Mepolizumab inhibits homing of these cells. The hypothesis is tested that mepolizumab affects the kinetics of these cells in blood and sputum.
Study design
three time points for sputum induction/analysis
10 time points for blood sampling/analysis
Intervention
Mepolizumab
PO Box 85500
L. Koenderman
Utrecht 3508 GA
The Netherlands
+31 (0)88 7557552
PO Box 85500
L. Koenderman
Utrecht 3508 GA
The Netherlands
+31 (0)88 7557552
Inclusion criteria
Age>18 and younger than 70 years
Diagnosis of eosinophil asthma despite use of corticosteroids
suitable for sputum induction
>2.5 % sputum eosinophils
Exclusion criteria
Any infection (e.g. HIV, hepatitis, STD's)
Insulin dependent diabetes
Smoking at present or in the last 12 months and/or a past
history of more than 10 pack years
Proven allergic bronchopulmonary aspergillosis
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL5988 |
| NTR-old | NTR6354 |
| Other | : 2016-001636-35 |